Cowen and Company reiterated their buy rating on shares of Immune Design Corp. (NASDAQ:IMDZ) in a research note released on Sunday morning.

Several other equities research analysts have also recently weighed in on the company. Jefferies Group reissued a buy rating and issued a $17.00 price objective (down from $20.00) on shares of Immune Design Corp. in a research report on Wednesday, August 10th. Zacks Investment Research raised Immune Design Corp. from a sell rating to a hold rating in a research report on Friday, August 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Immune Design Corp. presently has an average rating of Buy and an average price target of $13.50.

Immune Design Corp. (NASDAQ:IMDZ) opened at 8.30 on Friday. Immune Design Corp. has a one year low of $4.50 and a one year high of $23.55. The firm’s market cap is $210.89 million. The stock’s 50 day moving average is $6.97 and its 200 day moving average is $8.63.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Wednesday, November 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.11. The firm earned $8.20 million during the quarter, compared to analysts’ expectations of $1.73 million. Immune Design Corp. had a negative return on equity of 50.92% and a negative net margin of 415.05%. On average, equities research analysts expect that Immune Design Corp. will post ($2.46) earnings per share for the current year.

In other news, major shareholder Group L. P. Column bought 800,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was acquired at an average cost of $6.25 per share, for a total transaction of $5,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lewis W. Coleman bought 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was purchased at an average price of $6.25 per share, with a total value of $250,000.00. Following the completion of the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $312,500. The disclosure for this purchase can be found here. 42.90% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Venture Management LLC purchased a new position in shares of Immune Design Corp. during the third quarter worth approximately $16,738,000. Victory Capital Management Inc. purchased a new position in shares of Immune Design Corp. during the third quarter worth approximately $13,047,000. RS Investment Management Co. LLC raised its position in shares of Immune Design Corp. by 3.2% in the second quarter. RS Investment Management Co. LLC now owns 1,227,595 shares of the company’s stock worth $10,017,000 after buying an additional 38,123 shares during the last quarter. Pictet Asset Management Ltd. raised its position in shares of Immune Design Corp. by 768.9% in the second quarter. Pictet Asset Management Ltd. now owns 748,145 shares of the company’s stock worth $9,389,000 after buying an additional 662,045 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Immune Design Corp. by 18.6% in the third quarter. BlackRock Fund Advisors now owns 651,726 shares of the company’s stock worth $4,940,000 after buying an additional 101,990 shares during the last quarter. Institutional investors and hedge funds own 47.66% of the company’s stock.

About Immune Design Corp.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.